Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 open-label, single-arm study of neoadjuvant treatment of intratumoral
tavo-EP plus nivolumab IV infusion. Eligible participants will be those with pathological
diagnosis of operable locally-regionally advanced melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute